Scholarlink

<p>Impaired olfaction negatively impacts nutrition and appetite, particularly gaining more significance in cancer patients for whom nutrition and calorie intake are crucial. In our study, we aimed to investigate the effects of advanced-stage colorectal cancer treatment on olfactory functions. Fourteen patients (78.5% males, <i>n</i> = 11 and 21.5% females, <i>n</i> = 3) scheduled for Anti-VEGF (Bevacizumab) and FOLFOXIRI (folic acid, 5-flourouracyl, irinotecan, oxaliplatin) treatment due to advanced-stage cancer colorectal cancer were voluntarily participated in our study. Objective smell tests were conducted using the Sniffin’s stick battery before the start of treatment. After 3 months, tests were repeated to investigate the treatment’s effects. The average age of participants was 58.4 ± 8.5 years. The mean values of the threshold (T), discrimination (D), identification (I), and total (TDI) scores before treatment were found to be 9.43 ± 3.76, 11.92 ± 2.86, 12.71 ± 1.63, and 34.07 ± 5.79, respectively. After treatment, the mean scores for T, D, I, and TDI were 9.29 ± 3.53, 11.42 ± 2.84, 12.71 ± 1.59, and 33.43 ± 5.88, respectively. Statistically significant decrease was observed in post-treatment D and TDI scores (<i>p</i> = 0.015 and <i>p</i> = 0.035, respectively). FOLFOXIRI combined with Bevacizumab, may affect olfactory functions Informing patients about this aspect before treatment could be beneficial.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Olfactory Effects of Chemotherapy Combined with Bevacizumab on Advanced-Stage Colorectal Cancer Patients

  • 期刊论文

  • 发表日期：

    2025年1月2日

查看全文
  • Eray Uzunoğlu,
  • Alper Ceylan,
  • Fakih Cihat Eravcı,
  • Muammer Melih Şahin,
  • Süleyman Cebeci,
  • Ozan Yazıcı,
  • Banu Tijen Ceylan

摘要

Impaired olfaction negatively impacts nutrition and appetite, particularly gaining more significance in cancer patients for whom nutrition and calorie intake are crucial. In our study, we aimed to investigate the effects of advanced-stage colorectal cancer treatment on olfactory functions. Fourteen patients (78.5% males, n = 11 and 21.5% females, n = 3) scheduled for Anti-VEGF (Bevacizumab) and FOLFOXIRI (folic acid, 5-flourouracyl, irinotecan, oxaliplatin) treatment due to advanced-stage cancer colorectal cancer were voluntarily participated in our study. Objective smell tests were conducted using the Sniffin’s stick battery before the start of treatment. After 3 months, tests were repeated to investigate the treatment’s effects. The average age of participants was 58.4 ± 8.5 years. The mean values of the threshold (T), discrimination (D), identification (I), and total (TDI) scores before treatment were found to be 9.43 ± 3.76, 11.92 ± 2.86, 12.71 ± 1.63, and 34.07 ± 5.79, respectively. After treatment, the mean scores for T, D, I, and TDI were 9.29 ± 3.53, 11.42 ± 2.84, 12.71 ± 1.59, and 33.43 ± 5.88, respectively. Statistically significant decrease was observed in post-treatment D and TDI scores (p = 0.015 and p = 0.035, respectively). FOLFOXIRI combined with Bevacizumab, may affect olfactory functions Informing patients about this aspect before treatment could be beneficial.